<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281552</url>
  </required_header>
  <id_info>
    <org_study_id>A3921215</org_study_id>
    <secondary_id>TOFACITINIB QD P3</secondary_id>
    <nct_id>NCT02281552</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 week study that will evaluate the efficacy and safety of the 11 mg tofacitinib
      modified release tablet taken once a day in patients with rheumatoid arthritis who continue
      taking methotrexate. Results for the modified release tablets will be compared to the
      efficacy and safety of the 5 mg tofacitinib immediate release tablets taken twice a day in
      patients with rheumatoid arthritis who continue taking methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2014</start_date>
  <completion_date type="Actual">March 15, 2017</completion_date>
  <primary_completion_date type="Actual">March 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Activity Score in 28 joints using 4 variables (C-reactive protein)</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DAS28-4(ESR) change from baseline at week12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activitiy Score (DAS) remission</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low disease activity at week12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionaire (HAQ) improvement rate (0.22) at week12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 36-Item Short Form Healthy Survey (SF-36) at week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functional Assessment of Chronic Illness Therapy-Fatgue (FACIT-F) at week12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Euro Quality of Life (EQ-5D) at week12</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>tofacitinib modified release tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tofacitinib immediate release tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks</description>
    <arm_group_label>tofacitinib modified release tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks</description>
    <arm_group_label>tofacitinib immediate release tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of rheumatoid arthritis

          -  currently taking a stable dose of methotrexate

          -  no evidence of active or latent or inadequately treated tuberculosis

        Exclusion Criteria:

          -  evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or
             allergic disease

          -  clinically significant infections within the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daiichi Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toyohashi Medical Center</name>
      <address>
        <city>Toyohashi</city>
        <state>Aichi</state>
        <zip>440-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamada Rheumatology Clinic</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>790-0905</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Rheumatism Clinic</name>
      <address>
        <city>Takasaki-shi</city>
        <state>Gunma</state>
        <zip>370-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inoue Hospital</name>
      <address>
        <city>Tohrimachi, Takasaki</city>
        <state>Gunma</state>
        <zip>370-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima Red Cross Hospital &amp; Atomic-bomb Survivors Hospital</name>
      <address>
        <city>Hiroshima-city</city>
        <state>Hiroshima</state>
        <zip>730-8619</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Asahikawa Medical Center</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>070-8644</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katayama Orthopaedic Rheumatology Clinic</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>078-8243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshida orthopaedics and rheumatologyclinic</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komagamine Rheumatoid Orthopaedic Clinic</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sagamihara National Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Yokohama Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>245-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaki Citizen Hospital</name>
      <address>
        <city>Oosaki</city>
        <state>Miyagi</state>
        <zip>989-6183</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital/ Department of Hematology and Rheumatology</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>9808574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagano Red Cross Hospital</name>
      <address>
        <city>Nagano-shi</city>
        <state>Nagano</state>
        <zip>380-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sasebo Chuo Hospital</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <zip>857-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Ureshino Medical Center</name>
      <address>
        <city>Ureshino-shi</city>
        <state>Saga</state>
        <zip>843-0393</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soshigayaokura clinic</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honjo Rheumatism Clinic</name>
      <address>
        <city>Takaoka-shi</city>
        <state>Toyama</state>
        <zip>933-0874</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyasato Clinic</name>
      <address>
        <city>Shunan</city>
        <state>Yamaguchi</state>
        <zip>745-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Chiba-East Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sugimoto rheumatology and internal medicine clinic</name>
      <address>
        <city>Fukui</city>
        <zip>910-0068</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHONO Rheumatism Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>814-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sagawa Akira Rheumatology Clinic</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsubara Mayflower Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>673-1462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minami Kyosai Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>236-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Orthopaedic Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kyoto Daiichi Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>605-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oribe Clinic of Rheumatology and Internal Medicine</name>
      <address>
        <city>Oita</city>
        <zip>870-0823</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otsuka Clinic of Rheumatism and Medicine</name>
      <address>
        <city>Oita</city>
        <zip>870-1155</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabbit Clinic</name>
      <address>
        <city>Saitama</city>
        <zip>336-0911</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hirose Clinic</name>
      <address>
        <city>Saitama</city>
        <zip>359-1111</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921215&amp;StudyName=A%20study%20to%20evaluate%20the%20safety%20and%20efficacy%20of%20tofacitinib%20modified%20release%20tablets%20compared%20to%20tofacitinib%20immediate%20release%20tablets%20in</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2014</study_first_posted>
  <last_update_submitted>April 16, 2017</last_update_submitted>
  <last_update_submitted_qc>April 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tofacitinib, CP-690,550, Janis kinase, JAK inhibitor, modified release, Xeljanz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:
http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>March 12, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

